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ABSTRAK
Hemoglobin S (HbS, α2β2
6GluVal) merupakan variasi hemoglobin yang terbentuk 
hasil daripada mutasi GAG GTG pada kodon 6 gen β-globin. Hemoglobinopati 
haemoglobin S (HbS) jarang ditemui di kalangan penduduk Malaysia tetapi 
selalunya dijumpai di kalangan pendatang asing dari Afrika. Walau bagaimanapun 
beberapa kes didapati dalam kaum India dan Melayu. Kajian ini meninjau 
keputusan makmal pesakit HbS dan penggunaan “multiplex ligation-dependent 
probe amplification” (MLPA) dan “flow-through hybridization” (FTH) dalam 
mengesan mutasi HbS. HbS dikenalpasti melalui kromatografi cecair prestasi tinggi 
(HPLC) dan/atau elektroforesis kapilari serta elektroforesis hemoglobin. Analisis 
molekul dijalankan menggunakan kaedah MLPA, FTH dan penjujukan Sanger.  
Dua warga Afrika, tiga Melayu dan dua India berusia antara 2-31 tahun telah 
dikenalpasti. Lima pesakit adalah HbS homozigot, seorang kompaun heterozigot 
HbS/β-talasemia dan seorang lagi pembawa HbS. Tahap hemoglobin (Hb) kes 
HbS homozigot adalah antara 7.4-10.2 g/dL dengan aras HbS dan HbF diantara 
58.3-94.7% dan 1.5-35.5%. Hb untuk kes kompaun heterozigot HbS/β-talasemia 
adalah 5.8 g/dL dan normal pada pembawa HbS. Aras HbS, HbF dan HbA2 untuk 
HbS/β-talasemia dan pembawa HbS adalah 67%, 27.2% dan 4.2%, dan 38.6%, 
0.1% and 2.8% setiap satu. Kedua-dua kaedah MLPA dan FTH berjaya mengesan 
mutasi HbS dalam semua kes, manakala cuma FTH dapat menentukan zygositi 
mutasi HbS dan β-talasemia dalam satu ujian yang sama.
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Kata kunci: hemoglobin, reaksi rantaian multipleks polimerase, sabit
ABSTRACT
Haemoglobin S (HbS, α2β2
6GluVal) is a variant haemoglobin resulted from 
GAGGTG mutation on codon 6 of HBB gene. HbS haemoglobinopathy is 
uncommon in Malaysia and mainly seen in immigrants. However, Malaysian 
Indians and Malays are rarely affected. This study reviewed the laboratory findings 
of patients with HbS and the utilization of multiplex ligation-dependent probe 
amplification (MLPA) and flow-through hybridization (FTH) in the detection of 
HbS mutation. HbS was identified and quantified by high performance liquid 
chromatography (HPLC), capillary electrophoresis (CE) and cellulose acetate gel 
electrophoresis. Molecular analysis was performed using MLPA, FTH and Sanger 
Sequencing. Two Africans, three Malays and two Indian individuals aged between 
2-31 years were identified from our laboratory. Five patients were homozygous 
HbS, one was compound heterozygous HbS/β-thalassemia and one was a carrier 
of HbS. The patients with homozygous HbS had their haemoglobin (Hb) ranging 
from 7.4-10.2 g/dL with HbS and HbF levels of 58.3-94.7% and 1.5-35.5%, 
respectively. The Hb of compound heterozygous HbS/β-thalassaemia patients was 
5.8 g/dL and was normal in heterozygous HbS. HbS, HbF and HbA2 levels for the 
HbS/β-thalassaemia and the carrier were 67%, 27.2% and 4.2%, and 38.6%, 0.1% 
and 2.8%, respectively. Both MLPA and FTH successfully detected HbS mutation 
in all cases but only FTH could identify the zygosity of the HbS mutation together 
with underlying concomitant β-thalassaemia in a single test. 
Keywords: hemoglobin, multiplex polymerase chain reaction, sickle
reduced solubility under deoxygenated 
conditions (Magdoff-Fairchild et al. 
1976), especially in homozygous and 
some compound heterozygous states, 
that renders it to polymerise and lead 
to sickling of red blood cells.
 Haemoglobin analysis via High 
Performance Liquid Chromatography 
(HPLC), Capillary Electrophoresis 
(CE) and cellulose   acetate  gel  
electrophoresis have been well 
established for the diagnosis of 
HbS (Wajcman & Moradkhani 
2011). Measurements of HbS, 
INTRODUCTION
Sickle haemoglobin, HbS, a variant 
β-globin chain, is a product of a 
missense mutation (GAGGTG) 
at position 6 of the HBB gene 
substituting glutamic acid for valine 
whose molecular alteration was first 
described in 1977 (Marotta et al. 1977). 
The sickle mutation can be inherited 
in heterozygous form as HbS trait, 
in homozygous form as sickle cell 
anemia or compound with another 
β-gene mutation or deletion. HbS has 
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HbA, HbF and HbA2 levels and 
simultaneous detection of variant 
haemoglobin is useful in determining 
heterozygosity, homozygosity and 
possible compound heterozygosity 
of HbS. However, in instances where 
the clinical presentation and other 
laboratory findings are atypical, or in 
patients previously exposed to blood 
transfusions or hydroxyurea, molecular 
genotyping is needed for confirmation.
 Definitive diagnosis of HbS 
haemoglobinopathy requires 
molecular analysis. Several molecular 
methods have been established to 
detect presence of the typical mutation. 
The common methods employed 
include polymerase chain reaction 
(PCR) based Restriction Fragment 
Length Polymorphism (RFLP) and 
Allele-Specific Amplification (ASA)
(Hafiza et al. 2010). More recently, 
advanced technologies have paved 
ways for several other methods such 
Mutilple Ligation Probe Amplification 
(MLPA), a method which makes use 
of multiple probes to quantitatively 
amplify gene segments of interest 
depending on the test kits used.  A 
fluorescent labelled universal tagged to 
each primer set with unique fragment 
length once amplified will give rise 
to quantifiable signals for detection 
(Harteveld et al. 2014).  This method is 
able to screen for unknown mutations 
in beta gene as well as HbS mutation 
in a single test.  However, confirmation 
by DNA sequencing must still follow.  
Another method, reversed dot blot 
(RDB) has been around for several 
years but more recently, improvement 
of this technique by way of hybridising 
several biotinylated primers on a single 
membrane has led to production of 
RDB-flow through hybridisation (FTH), 
able to amplify 25 known mutations, 
including two deletions, also in a single 
run (Lin et al. 2012)
 We reviewed the laboratory features 
of heterozygous HbS, homozygous 
HbS and compound heterozygous 
HbS/β-thalassaemia patients 
diagnosed in our centre. We also 
reviewed the utilization of MLPA and 
FTH techniques in molecular diagnosis 
of HbS. 
MATERIALS AND METHODS
Clinical Presentations, 
Haematological Parameters and 
Haemoglobin Analysis
This was a retrospective study of seven 
patients with HbS haemoglobinopathy 
presented to UKMMC from year 2008 
to 2017. The index case of a family 
study of HbS published by Hafiza et 
al. (2010) was included in our current 
case series as Patient 6.
 Demographic data and clinical 
manifestations of the patients were 
collected through review of patients’ 
medical records. Full blood count 
(FBC) was performed using automated 
haematology analyzer, DxH800 
(Beckman Coulter, CA, USA) or XN-
3000 (Sysmex Corporation, Kobe, 
Japan). Haemoglobin analysis of 
six patients were performed at our 
laboratory. Haemolysates of the 
samples were analysed with HPLC 
and/or CE to measure haemoglobin 
subtypes. HPLC was carried out on 
VARIANT II β-Thalassemia Short 
Program (Bio-Rad Laboratories, 
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Hercules, CA, USA) and CE utilised 
Sebia Capillarys 2 System (Sebia, Paris, 
France). Haemoglobin electrophoresis 
was carried out on a Microtech648ISO 
(Interlab, Italy) at alkaline pH and on 
an Interlab G26 (Interlab, Italy) at 
acidic pH to confirm the presence of 
HbS. Results of haemoglobin analysis 
of patient 7 were obtained from his 
previous investigations in a private 
laboratory.  
DNA Extraction
Genomic DNA was extracted from 
white blood cells (WBC) of the EDTA-
anticoagulated peripheral blood 
samples using the Blood Mini DNA 
Kit (Qiagen GmbH, Hilden, Germany) 
following the manufacturer’s 
instructions. The DNA concentration 
and purity were determined 
spectrophotometrically at 260 and 280 
nm and DNA samples were stored at 
-300C before use.
Multiplex Ligation-dependent 
Probe Amplification (MLPA)
SALSA MLPA KIT P102 HBB kit (MRC 
Holland, Amsterdam, the Netherlands) 
was used to analyse LCR, HBE, 
HBG2, HBG1, HBD and HBB regions 
according to the manufacturer’s 
guidelines. Approximately 200 ng of 
genomic DNA were obtained from 
each MLPA sample. ABI 9600 Thermal 
Cycler (Applied Biosystems, Foster 
City, CA, USA) was used for ligation 
and amplification process. PCR 
amplification was carried out for 33 
cycles at 94oC for 30 seconds, 60oC for 
30 seconds and 72oC for 60 seconds.  
Final extension was carried out at 
72oC for 20 minutes. ABI PRISM 3130 
Genetic Analyzer (Applied Biosystems, 
Foster City, CA, USA) was used to 
separate the amplified fragments.  The 
results were analysed by My Coffylyser.
Net (MRC Holland, Amsterdam, the 
Netherlands). 
Flow-through Hybridization (FTH)
Four cases were further analysed via 
flow-through hybridization technology 
using Hybriobio Thalassemia Gene 
Diagnostic Kit Thal-b25MY (Hybribio 
Limited, Hong Kong, China). The 
diagnostic kit was designed to detect of 
the following 23 point mutations and 
2 deletional β-globin gene mutations: 
IVS 1-5 (G>C), IVS 1-1 (G>T), CD 41/42 
(-TCTT), CD 17 (A>T), TATA -28 (A>G), 
TATA -29 (A>G), IVS II-654 (C>T), 
CD 71/72 (+A), CD 43 (G>T), IVS 1-1 
(G>A), CD 27/28 (+C), Initiation Codon 
(T>G), CD 26 (G>A) (HbE), CD 19 
(A>G) (Hb Malay), CD 6 (A>T) (HbS), 
CD 6 (G>A) (HbC), Poly A (A>G), Cap 
Site +1 (A>C), -86 (C>G), -88 (C>T), 
CD 15 (G>A), CD 16 (-C), CD 35 (-C), 
45 kb deletion (Filipino) dan 619 bp 
deletion (Norunaluwar et al. 2015). The 
hybridization process was performed 
following manufacturer’s protocol. 
Sanger’s Sequencing
Polymerase chain reaction (PCR) 
amplification of 4 fragments (I-IV) 
which include the region of HBB gene 
was performed.  Four sets of primers 
were used (First Base, Malaysia), the 
sequence of which are listed in Table 
1. PCR was performed using My Cycler 
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(Bio-Rad Laboratories, Hercules, CA, 
USA). The PCR reactions consisted of 
0.4μM of forward and reverse primers, 
1.0U of Taq DNA polymerase, 50 ng 
of template DNA, 2 mM of MgCl2, 0.2 
mM of dNTP’s and 1.5x of PCR buffer 
(Promega, USA). For fragment 1 and 
4, the PCR conditions involved initial 
denaturation at 95˚C for 15 minutes, 
30 cycles of denaturation step at 95˚C 
for 1 minute, annealing temperature 
from 59˚C for 1 minute and extension 
at 72˚C for 1 minute and 30 seconds 
followed by final extension at 72˚C for 8 
minutes. For fragment 2 and 3, the PCR 
conditions were similar to the above, 
but annealing was performed at 53˚C 
for 1 minute. DNA sequencing utilised 
ABI 3100 Genetic Analyzer (Applied 
Biosystem, USA). Purification of the 
PCR products were used commercially 
available kit (Qiagen, Germany). The 
sequencing reactions were run on 
Big Dye Terminator Kit V3.1 (Applied 
Biosystem, USA) following these 
reactions; 10 ng/μl of purified PCR 
products, 2μμl of Big Dye Terminator 
Kit V3.1, 3 μl of Sequencing Buffer, 3.2 
pmol of primer in a total volume of 20 
μl. Cycle sequencing was performed 
using 40 cycles and consisted of 96˚C 
at 1 minute, 96˚C at 10 seconds and 
50˚C at 5 seconds and 60˚C for 4 
minutes. Purification of the products of 
cycle sequencing were peformed using 
ethanol/sodium acetate precipitation 
technique. Finally, standard method 
was used to sequence the products 
using Applied Biosystem, USA. 
Analysis of the sequencing results was 
performed on Basic Local Alignment 
System Tools (BLAST). 
RESULTS
Seven patients with HbS 
haemoglobinopathy have been 
identified. The patients ranged 
from two to 31 years at the time of 
diagnosis at Universiti Kebangsaan 
Malaysia Medical Centre (UKMMC). 
They were Africans, three Malays 
and two Malaysian Indians. Five of 
the patients were homozygous HbS, 
one was compound heterozygous 
HbS/β-thalassemia and one was 
heterozygous HbS. All patients 
were not on hydroxyurea and had 
no history of blood transfusion in 
the preceeding three months at the 
time of haemoglobin analysis was 
performed. Demographic data and 
clinical presentations of the patients 
are summarized in Table 2.  Patient 4 
and 5 were siblings.
Haematological Values and 
Haemoglobin Analysis
Haemoglobin levels of homozygous 
Fragments Forward primer sequence Reverse primer sequence
1 5’TGAAGTCCAACTCCTAAGCCA3’ 5’CAACTTCATCCACGTTCACC
2 5’GGTGAACGTGGATGAAGTT3’ 5’CTAAAACGATCCTGAGACTCCCA3’
3 5’GTGTACACATATTGACCAAA3’ 5’AGCACACAGACCAGCACG TT3’
4 5’AACGTGCTGGTCTGTGTGCT3’ 5’AAATGCACTGACCTCCCACAA3’
Table 1: Primer sequences used for PCR reactions in DNA sequencing process
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HbS patients ranged from 7.4-10.2 g/dL, 
5.8 g/dL in the compound heterozygous 
HbS/β-thalassaemia patient and was 
normal in heterozygous HbS patient 
(Table 2). Four out of five homozygous 
HbS patients showed normochromic 
normocytic RBCs. In the homozygous 
patient with hypochromic microcytic 
feature, concomitant iron deficiency 
and α-thalassemia could not be 
fully excluded. HbS, HbF and HbA2 
levels ranged from 58.3-94.7%, 1.5-
35.5%, 1.1-3.8%, respectively among 
homozygous HbS; 67%, 27.2%, 4.2% 
in compound heterozygous HbS/β-
thalassemia and 38.6%, 0.1%, 2.8%, 
respectively in the heterozygous HbS. 
HbA was absent in the homozygotes 
of HbS and compound heterozygotes 
of HbS/β-thalassemia patients. 
Molecular Analysis
MLPA successfully detected HbS 
mutation (HBB:c.20A>T, rs334) in all 
seven cases (Figure 1).  However, this 
method was unable to distinguish 
between homozygous and 
heterozygous states of the mutation.  
Four cases (Patient 2, 3, 6, 7) were 
Patient Age* / 
Gender
Race Diagnosis Clinical Presentations
1 23 /
Female
Nigerian Homozygous 
HbS
•History of recurrent painful crises requiring 
hospitalization.
•Demised at the age of 23 due to massive 
subarachnoid haemorrhage secondary to ruptured 
anterior communicating artery aneurysm.
2 27 /
Male
Nigerian Homozygous 
HbS
•Recurrent pain crises requiring hospitalization and 
intravenous opioids
3 31 /
Male
Malay Heterozygous 
HbS
•Detected upon family screening (daughter known 
case of HbS trait).
•No documented HbS related sign and symptom.
4 11 /
Female
Indian Homozygous 
HbS
•Detected during investigations for neonatal 
jaundice (mother known case of homozygous HbS)
•Presented with single episode of haemolytic crisis 
and acute chest syndrome (? triggered by infection).
5 2 /
Male
Indian Homozygous 
HbS
•Detected during anaemia workout and family 
screening at infancy (siblings of patient no. 4)
•History of neonatal jaundice; otherwise presented 
with asymptomatic anemia.
6 14 /
Female
Malay Homozygous 
HbS
•Jaundice since 11 years old, developed deep vein 
thrombosis (at 14 years old) and bilateral lower limb 
bone infarct (no avascular necrosis). 
•Multiple pain crises requiring hospitalization.
•Cholecystectomy and splenectomy were performed 
in the later years.
7 2 /
Male
Malay HbS/β 
thalassemia
•Diagnosed at 1 year old in a private hospital.
•Recurrent haemolytic crises, first presented with 
jaundice at 4 months old.
*age upon diagnosis at UKMMC 
Table 2: Demographic data and clinical manifestations of patients with HbS 
haemoglobinopathy.
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Figure 1: MLPA demonstrating presence of HbS mutation (HBB:c.20A>T, rs334)  (highlighted red).
Figure 2: Flow-through Hybridization using HybriMem (Hybribrio, Hong Kong, China). (a) Location 
of probes designed in the membrane template. Red box indicates codon 6 and yellow box for Codon 
41/42 of β-gene. Top rows show wild type alleles and bottom rows show alleles with mutation / 
deletion. (b) Homozygous HbS mutation showing presence of CD6 (A>T) (HbS) with absence of the 
wild type allele (Patient 6): a single dot within red box.  (c)  Heterozygous HbS mutation showing 
presence of both CD 6 (A>T) (HbS) and wild type allele (Patient 3): double dots within red box. (d) 
Compound heterozygous CD 6 (A>T) HbS and Codon 41/42 (-TCTT) β-gene mutations (Patient 7): 
double dots in both red and yellow boxes.
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subsequently analysed with FTH. 
Patient 3 showed heterozygous HbS 
mutation, Patient 2 and 6 showed 
homozygous HbS mutation and Patient 
7 showed compound heterozygous 
for HbS and Codon 41/42 (-TCTT) 
mutations (Figure 2).  DNA sequencing 
confirmed the HbS genotypes of all 
seven cases (Figure 3) and concomitant 
β-thalassemia in patient 7. In addition, 
patients 4 and 5 were found to carry 
additional mutations of heterozygous 
c.9T>C and homozygous IVS-II-16 
G>C (Table 3). DNA analysis for 
α-thalassemia was also carried out 
on patient 2 in view of hypochromic 
microcytic picture but failed to detect 
presence of any HBA gene mutation or 
deletion based on panels available in 
our laboratory (Azma et al. 2014).
DISCUSSION
Sickle haemoglobinopathy is an 
inheritable condition secondary 
to A>T mutation in codon 6 of 
the β-globin gene leading to HbS 
formation. The resultant replacement 
of hydrophilic glutamic acid by 
the hydrophobic valine causes the 
intracellular HbS to become insoluble 
and polymerize upon deoxygenation. 
The long polymers of HbS in turns 
distort the RBCs into stiff, sickle shape 
with reduced deformability. Repeated 
or prolonged sickling progressively 
damages the RBC membrane, 
contributing to shortened RBC lifespan 
and haemolytic anemia. The reduced 
deformability and increased stiffness, 
along with abnormal adhesion of the 
sickle RBCs to vessel endothelium, 
lead to vaso-occlusion and splenic 
sequestration. These events eventually 
gives rise to a broad range of acute 
and chronic ischaemic clinical 
complications (Kato et al. 2017).  Several 
genetic modifiers have been described 
to influence HbS haemoglobinopathy 
phenotypes. This includes 
coinheritance with α-thalassemia trait 
and one’s ability to produce HbF. 
(Steinberg & Sebastiani 2012; Thein 
2017). Compound heterozygous HbS/
Figure 3: DNA sequencing showing HbS mutation (CD 6 A>T). (highlighted yellow) (a) Heterozygous 
HbS mutation.   (b) Homozygous HbS mutation. 
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β0-thalassemia generally has similar 
clinical picture to homozygous HbS 
but with less severe haemolysis (Sokal 
et al. 2016). Heterozygous HbS are 
generally asymptomatic due to the 
lower level of intracellular HbS in 
the RBCs. However, complications 
related to vaso-occlusion such as renal 
papillary necrosis, splenic infarction 
and haematuria have been observed 
(El Ariss et al. 2016)
 HbS haemoglobinopathy is 
uncommon in Malaysia, with isolated 
case reports describing the disease 
mainly in Malaysia Indians and 
occasionally Malays.  The cases were 
either homozygous HbS or compound 
heterozygous with beta thalassaemia, 
another inherited beta globin disorder 
common in Malaysia.  Both forms 
showed similar clinical spectrum and 
disease presentation (Lie-Injo et al. 
1986; Hafiza et al. 2010). Rahimah et 
al. reported a rare case of sickle/HbD-
Punjab disease in a young Indian boy 
presented with severe anaemia during 
infancy (Rahimah et al. 2014).
 Under basal conditions, 
heterozygous HbS individuals 
show no obvious haematologic 
abnormality with normal haemoglobin 
concentration and RBC indices. 
Concomitant α-thalassaemia or iron 
deficiency anaemia may produce a 
hypochromic microcytic picture. The 
usual partition of HbA and HbS is 
approximately 60:40 ratio, owing to 
the greater post-translational affinity 
of α-globin chains for βA than for βS 
(Saunthararajah & Vichinsky 2013).
 Homozygous HbS usually has 
haemoglobin levels around 6-9 g/
dL (Yawn et al. 2014) and anaemia is 
usually normochromic normocytic 
without α-thalassaemia or iron 
deficieny. HbS usually constitutes 
80-95% of total haemoglobins, with 
HbF levels of 5-15%, HbA2 of <3.5% 
and absence of HbA (Ware et al. 
2017). Compound heterozygous HbS/
β0-thalassemia shows hypochromic 
microcytic anemia with similar ranges 
Patient MLPA Flow-through Hybridization DNA Sequencing
1 HbS mutation detected Not performed Homozygous HbS mutation
2 HbS mutation detected HbS mutation detected Homozygous HbS mutation
3 HbS mutation detected HbS mutation and wild type 
alleles detected
Heterozygous HbS mutation
4 HbS mutation detected Not performed Homozygous HbS mutation
Heterozygous HBB c.9T>C
Homozygous IVS-II-16 G>C
5 HbS mutation detected Not performed Homozygous HbS mutation
Heterozygous HBB c.9T>C
Homozygous IVS-II-16 G>C
6 HbS mutation detected HbS mutation detected Homozygous HbS mutation
7 HbS mutation detected HbS mutation and wild type 
alleles detected
Codon 41/42 (-TCTT) and wild 
type alleles detected
Heterozygous HbS mutation
Heterozygous Codon 41/42 (-TCTT)
Table 3: Summary of molecular analysis of patients with HbS haemoglobinopathy
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of HbS, HbF and absence of HbA as 
in homozygous HbS, but typically 
has raised HbA2 level (>3.5%)(Ware 
et al. 2017). However, HbA2 higher 
than 3.5% has been reported in 
homozygous HbS, some being linked 
to concomitant α-thalassaemia (Da 
Fonseca et al. 2015).
 High level of HbF is observed in 
homozygous HbS. HbF level varies 
across different HbS haplotypes, in 
the descending order of Arab-Indian, 
Senegal, Benin and Bantu haplotypes. 
(Steinberg & Sebastiani 2012). However, 
HbF level shows considerable variation 
within any haplotype group as well 
(Steinberg & Sebastiani 2012).  A study 
by Akinsheye et al. reported HbF 
levels of 18-41%  in a group of Saudi 
Arabian homozygous HbS patients. 
Other than that, coinheritance with 
non-deletional HPFH inevitably raises 
the HbF level. Several quantitative trait 
locus (QTL) has also been linked to 
high HbF level in homozygous HbS,  
namely Xmn1-HBG2, HBS1L-MYB 
intergenic region (HMIP) and BCL11A 
(Akinsheye et al. 2011; Thein 2017). 
Because of this overlap in values, 
HbF level is sometimes less useful in 
discriminating HbS/β0-thalassaemia 
from homozygous HbS.
 HbF has been recognized as an 
important modulator of homozygous 
HbS phenotypes due to its inhibitory 
effect on deoxy HbS polymerization. 
This is because HbF cannot enter the 
deoxy HbS polymer phase and it also 
reduces intracellular HbS concentration 
(Steinberg et al. 2014). Therefore, 
HbS patients with higher HbF level 
are generally associated with milder 
haematologic and clinical features. 
Patient 5 from our study showed the 
highest level of HbF (35.5%) with the 
least eventful clinical course among 
the homozygous HbS patients (Table 
2). His sister, Patient 4, with a similarly 
high HbF level (29.9%), presented 
with less frequent complications. 
However, recent studies mentioned 
that it was the amount of HbF per 
F-cell (HbF/F cell) and the proportion 
of F-cells with sufficient HbF to inhibit 
HbS polymerization, rather than F-cell 
number or overall HbF concentration, 
were better predictors of clinical 
severity in homozygous HbS (Steinberg 
et al. 2014). It was proposed that a HbF 
concentrations nearing 30% is required 
for amount of protected cells to reach 
70% (Steinberg et al. 2014). This may 
explain why multiple vaso-occlusive 
events still occurred in Patient 6 who 
had HbF level of 17.1%.  
 Molecular studies is vital to confirm 
the presence of HbS mutation. Some 
molecular methods can simultaneously 
detect the zygosity status of the 
mutation. This is crutial in cases where 
clinical presentations or test results 
are atypical or in patients previously 
exposed to blood transfusions 
or hydroxyurea that may affect 
haemoglobin analysis interpretation. 
Various methods had been established 
for the purpose, including RDB, RFLP 
and ASA. Other available molecular 
methods include MLPA, RDB-FTH 
and High Resolution Melting analysis 
(HRM).
 MLPA is one of the molecular 
methods useful for multiple detection 
of genetic deletions and duplications 
in HBA and HBB genes (Greene 
et al. 2015). The MLPA kit for the 
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β-thalassaemia also includes HbS 
mutation (HBB:c.20A>T, rs334). 
However, unlike in gene deletions 
or duplications, MLPA is not useful 
in identifying the homozygosity or 
heterozygosity status of the mutation. 
Limited literature is available on the 
study of HbS mutation using MLPA up 
to the current date. 
 FTH, initially developed for HPV 
detection, was later introduced for 
the diagnosis of α-, β-thalassaemia 
and haemoglobinopathy. FTH has 
the advantage of genotyping samples 
as heterozygotes, homozygotes or 
compound heterozygotes in a single 
run (Lin et al. 2012). The method is also 
less laborious and yields more rapid 
results in comparison to some of the 
conventional molecular techniques. 
However, the limitation lies in its ability 
to detect unknown mutations, as it 
is only based on the selected primer 
panel used (Lin et al. 2012). As with 
MLPA, HbS mutation analysis using 
this technique has not been widely 
studied.  
 DNA sequencing provides 
confirmation for the presence of HbS 
mutation and the zygosity status. 
It also identifies other concomitant 
gene deletion and/or mutation in the 
β-globin genes clusters, depending on 
the segments of HBB tested. In this case 
series, Codon 41/42 (-TCTT) β-gene 
mutation, a type of β0 thalassaemia, 
was detected along with HbS mutation 
in the HbS/β-thalassaemia patient 
(Patient 7). 
 Other than that, DNA sequencing 
had also detected two additional 
mutations, HBB c.9T>C and IVS-
II-16 G>C, in Patient 4 and 5. A silent 
mutation, HBB c.9T>C, was found to 
be the most common mutation on HBB 
gene among an urban eastern Indian 
population (19.57%) in Odisha, India 
(Sahoo et al. 2014). The same study 
also detected an increased frequency 
of IVS-II-16 G>C in the population.  
Another study from Bangladesh also 
reported that these two mutations 
were common among their local 
population (Sultana et al. 2016). The 
second study observed that HBB 
c.9T>C produced no pathogenic effect 
when present alone or in the presence 
of homozygous IVS-II-16 G>C,but may 
generate thalassaemia when present 
in homozygous state or coinherits 
with particular HBB mutations. 
Nevertheless, both mutations were 
found in healthy controls in either 
heterozygous or homozygous forms. 
Therefore, the author proposed that 
both HBB c.9T>C and IVS-II-16 G>C 
might be only a polymorphism with no 
pathogenic effect. 
 Molecular analysis for 
α-thalassaemia was performed on 
Patient 2 and showed no deletion 
or mutation detected. However, as 
the genotypes for α-thalassemia vary 
geographically, deletion or mutation 
uncommon in our setting and hence 
were not tested for, could have been 
missed. 
CONCLUSION
HPLC and CE have been widely 
employed for the detection and 
quantification of HbS. HbS level 
varies widely among homozygous 
HbS patients, being affected by the 
level of HbF. Overlapping HbF and 
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HbA2 levels can be seen between 
homozygous HbS and HbS/β0- 
thalassemia. Both MLPA and FTH are 
effective in detecting the presence 
of HbS mutation but MLPA is unable 
to determine the zygosity status. On 
the contrary, FTH can concurrently 
identify HbS mutation, wild type allele 
and other concomitant deletional 
or non-deletional β-globin gene 
mutations. This advantage enables the 
determination of HbS mutation and to 
simultaneously identify homozygosity, 
heterozygosity and compound 
heterozygosity of the mutation. 
Nevertheless, more studies should be 
carried out to establish the roles of 
MLPA and FTH in the diagnosis of HbS 
haemoglobinopathy. 
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